Catapult BioAccel Funds Arizona Early Stage Biotech Company

Kemeta to Bring Revolutionary Palm-Size Fat Metabolism Analyzer to Market
PHOENIX--(Business Wire)--
Catapult BioAccel, formerly named CatapultBio, has announced the funding of an
Arizona-based early stage firm, Kemeta LLC, a company developing a revolutionary
product for application in consumer health and medical markets.

"We awarded funding to Kemeta based on its innovative technology, market
potential and the past success of its CEO," said MaryAnn Guerra, CEO and board
chairman of Catapult BioAccel, an Arizona-based nonprofit organization
established this year to accelerate new scientific ideas, transferring them into
commercial products and viable business ventures.

Kemeta, based in Mesa, Ariz., is developing a palm-size breath acetone analyzer
that measures fat metabolism in a single breath. Acetone is the known breath
biomarker for fat metabolism. Catapult BioAccel is funding a portion of the
activities that will advance the product development with a $200,000 grant from
its New Venture Development Program (NVDP). This validation process is a key
step on the path to commercialization and involves several clinical studies
specific to fat metabolism. Kemeta is collaborating with another Arizona
company, Kronos Science Laboratories, to perform the clinical studies over the
next several months.

"The funding from Catapult BioAccel is pivotal for us in terms of obtaining the
data necessary to validate product-use claims in advance of submittal to the FDA
for approval, a critical stage in the commercialization process," said Dr. Joan
Vrtis, CEO, president and founder of Kemeta.

Vrtis estimates Kemeta`s first product could be available to healthcare
professionals and consumers in 2010.

While there are billions of dollars available for basic research, relatively
little funding is accessible for the commercialization activities required to
make new technologies more alluring for venture capitalists and other investors.
With the grant, Catapult BioAccel fills one of two funding gaps for Kemeta that
could prevent the commercialization of its technology.

Catapult BioAccel is a fully independent nonprofit organization, based in
Phoenix, dedicated to translating life science discoveries into new business
opportunities that drive economic development by accelerating commercialization
of technologies with a focus on diagnostics, therapeutics, devices, tools and
services.

Denise Resnik & Associates
Denise D. Resnik
Nick Quan
602-956-8834
602-373-2400 (cell)

Copyright Business Wire 2009